Biotech company
IDEXX Laboratories has been consistently outperforming its competitors in terms of stock value. Many investment firms, including Wealthspire Advisors LLC, Private Advisor Group LLC, and GSA Capital Partners LLP have altered their stakes in the company, with notable new investments. Despite a rating downgrade to 'Hold' by StockNews.com, the company's strong performance caused an uplift in the market, with an impressive return on capital, offering a potential 136% gain to those who invested five years ago. Financial data indicates a strong balance sheet, with remarkable Q1 earnings surpassing estimates. However, caution may be warranted as insiders have recently sold off stock. The company's expertise in healthcare is recognized, particularly its in-clinic cellular analyzer,
IDEXX inVue Dx™. Despite an earnings beat, the company was hit by Q1 revenue miss and lowered FY24 guidance. Over the last decade, an investment of $100 in the company would now be worth $700. The company is known for its strong recurring revenues thanks to its consumables and software products. Businesses are bolstering their stakes while the company gears up for its 2024 investor day.
Idexx Laboratories IDXX News Analytics from Fri, 15 Sep 2023 07:00:00 GMT to Sun, 14 Jul 2024 13:42:14 GMT -
Rating 7
- Innovation 8
- Information 6
- Rumor 3
